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Abstract Renal function is the most important predictor
of clinical outcome in heart failure (HF). It is therefore
essential to have accurate and reliable measurement of
renal function and early speciﬁc markers of renal impair-
ment in patients with HF. Several renal functional entities
exist, including glomerular ﬁltration (GFR), glomerular
permeability, tubulointerstitial damage, and endocrine
function. Different markers have been studied that can be
used to determine changes and the effect of treatment in
these entities. In the present review, we summarize current
and novel markers that give an assessment of renal function
and prognosis in the setting of acute and chronic HF.
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Introduction
In patients with heart failure (HF), impaired renal function is
often present and one of the strongest predictors of clinical
outcome [1–4]. Both worsening renal function (WRF) and
acute kidney injury (AKI) are prevalent in patients with acute
and chronic HF and are associated with an increased mortality
andmorbidity[1,5,6].Inaddition,renaldysfunctionmightnot
only be a marker of a poor clinical condition, but might also
contribute to the development and progression of heart failure
[7]. Renal function and changes in renal function therefore
provide important clinical information in patients with HF.
Usually,‘‘renalfunction’’ isdeﬁned asthe ﬁltration ability
of the kidney, which can be expressed as the glomerular ﬁl-
trationrate(GFR).Creatinineandempiricalformulasthatare
mainly based on creatinine are used to estimate GFR in
patientswithHF[8].However,GFRdoesnotcovertheentire
function of the kidney, which also comprises of glomerular
permeability, tubular function, and several speciﬁc functions
such as vitamin D metabolism and erythropoietin produc-
tion. Therefore, several markers other than creatinine can be
used to estimate various functions of the kidney.
In the present review, we summarize current and novel
promising markers/ways to assess renal function and chan-
ges in renal function in patients with HF and their prognostic
potential in HF. We will focus on glomerular function,
glomerular permeability, and tubulointerstitial damage.
Table 1 gives an overview of the clinical characteristics of
the markers that will be discussed in the present review.
Glomerular ﬁltration rate
The golden standard of measuring GFR is by speciﬁc
markers such as iothalamate or inulin clearance. These
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suming and expensive and can, therefore, not be used in
daily clinical practice. In study cohorts, these techniques
have been used to validate easier estimations of GFR,
mostly in patients with chronic HF [8, 9]. Instead, different
markers that give an estimate of GFR are used as surrogate
markers for GFR.
Serum creatinine
Creatinine is a break down product of creatine phosphate,
which is normally formed at a constant rate in the skeletal
muscles. Upon presentation in the plasma, it is freely ﬁl-
tered through the glomerulus and appears in the urine.
Creatinine is, however, also actively secreted in the tubules
and accordingly its clearance overestimates true GFR to a
varying extent [10].
Increased serum creatinine is a common ﬁnding in
patients with acute and chronic HF and is a sign of renal
impairment. In large cohort studies and substudies of ran-
domized clinical trials, an increased serum creatinine level
was strongly associated with impaired clinical outcome
[11, 12]. However, serum creatinine levels are prone to bias
due to several shortcomings. First, the production of cre-
atine phosphate is not constant. Due to changes in muscle
Table 1 Properties of different markers
Detection ‘‘Validation’’ Relation with prognosis Pro’s Cons
Glomerular ﬁltration rate
Creatinine Serum
a CHF
AHF
Strong evidence Easy
Cheap
Interpretable
Exponential relationship with GFR
Dependent on muscle mass
(s)MDRD Serum CHF
Not in AHF
Strong evidence Valid
Accurate
Formula (calculation)
Less reliable in extremes of GFR
BUN Serum CHF
AHF
Emerging evidence Easy
Cheap
Interpretation difﬁcult
Cystatin C Serum
a CHF
AHF
Evidence in AHF Unbiased
Very reliable
Interpretation difﬁcult
Costs
Glomerular permeability
Albuminuria Urine CHF
Not in AHF
Strong evidence CHF Easy obtainable
Cheap
Additive to GFR
Low speciﬁcity
Tubulointerstitial damage
NAG Urine CHF
Not in AHF
Emerging evidence CHF Easy obtainable
Additive to GFR and
UAE
Strong marker of AKI
Low speciﬁcity
Costs
KIM-1 Urine CHF
Not in AHF
Emerging evidence CHF Easy obtainable
Additive to GFR and
UAE
Strong marker of AKI
Costs
NGAL Urine/
Serum
CHF
AHF
Emerging evidence CHF
and AHF
Easy obtainable
Additive to GFR and
UAE
Strong marker of AKI
Low speciﬁcity especially in serum
and in CHF
IL-18 Urine/
Serum
CHF
Not in AHF
Emerging evidence CHF Easy obtainable
Strong marker of AKI
Also strongly increased
in inﬂammation
FABP-1 Urine/
Serum
Not in CHF
Not in AHF
None Strong marker of AKI Elevated in sepsis
Also found in liver
AHF acute heart failure, AKI acute kidney injury, BUN blood urea nitrogen, CHF chronic heart failure, FABP fatty acid binding protein,
GFR glomerular ﬁltration rate, IL-18 Interleukin 18, KIM-1 kidney injury molecule 1, MDRD modiﬁcation of diet in renal disease (formula),
NAG N-acetyl-beta-D-glucosaminidase, NGAL neutrophil gelatinase-associated lipocalin, UAE urinary albumin excretion
a Can be measured in urine, but then does not resemble GFR
242 Heart Fail Rev (2012) 17:241–250
123mass, when wasting of muscles occurs with progression of
cardiac disease, changes in serum creatinine levels may
develop, which are not due to changes in GFR. The other
way round, a decrease in GFR may go unnoticed when it is
accompanied by muscle wasting, which is common in
severely and chronically ill patients, including HF patients
[8]. Second, serum creatinine shows an exponential rela-
tionship with invasively determined GFR. This exponential
relationship makes interpretation of changes in serum
creatinine difﬁcult (Fig. 1)[ 13]. Finally, active secretion of
creatinine signiﬁcantly hampers the interpretation of serum
creatinine, especially when renal function is compromised,
or in obese subjects, when the relative effect of active
secretion is most pronounced [14]. Importantly, serum
creatinine may be a good representative of the number of
functionally active nephron units. Serum creatinine may,
therefore, be a reasonable estimate of renal function at one
point in time and a strong risk marker, but with signiﬁcant
shortcomings for accurate assessment of GFR. Finally,
creatinine clearance may be used to estimate GFR. How-
ever, the overestimation due to tubular secretion of creat-
inine, and urine collection errors, render it unreliable,
although novel methods to correct for this may lead to
reappraisal of 24-h urine collection [15].
Estimated GFR, creatinine-based formulas
To overcome the problems that may arise with the use of
serum creatinine or creatinine clearance, as an estimate of
GFR, large (sub) studies have generated empirical formulas
that give a more reliable estimation of GFR based on serum
creatinine [13]. In addition to serum creatinine, they typi-
cally include age and gender, and sometimes weight, race,
blood urea nitrogen, and albumin. The most common for-
mulas are the Cockcroft-Gault equation, which is an esti-
mate of creatinine clearance, and the currently widely used
(simpliﬁed) Modiﬁcation of Diet in Renal Disease
(sMDRD/MDRD) formulas [13]. These formulas have
been validated in renal disease, and give a reasonably
accurate estimation of GFR, especially in patients with
chronic kidney disease and renal function impairment.
More recently, these formulas have been validated in
patients with chronic HF [8]. Smilde et al. showed that in
patients with relatively preserved renal function, the
6-variable MDRD formula showed the most accurate
estimation of GFR, with similar prognostic information
compared to real GFR [8]. However, all formulas, includ-
ing Cockcroft-Gault and (s)MDRD overestimate real GFR
in the lower levels of true GFR and underestimated real
Fig. 1 Relationship between serum creatinine and estimated GFR:
effect of change in serum creatinine. Different changes in estimated
GFR with similar changes in serum creatinine. A pronounced
decrease in GFR from normal—the ﬂat part of the curve—gives just
a subtle increase in serum creatinine that often stays within the
normal day-to-day variability of the assay and, therefore, may go
unnoticed. The other way round, a trivial further decrease in already
compromised GFR leads to a steep rise of creatinine, based on the
steepness of the curve here, that can lead to undue concern. For
example, a decrease in serum creatinine from point A to B results in
a decrease in eGFR of 15 ml/min/1.73 m
2. However, a decrease in
serum creatinine from point B to C results in a much more
pronounced decrease in eGFR of 75 ml/min/1.73 m
2. Depicted is the
GFR estimated by the simpliﬁed MDRD for a 70-year-old white
male
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123GFR in the higher levels of true GFR. Accordingly, in
clinical practice, when GFR decreases over a longer period
of time, the decrease will be underestimated by these
equations. Nevertheless, in numerous studies, both acute
and CHF showed that GFR as estimated by these formulas
(mostly sMDRD) is an important prognostic factor [2, 8,
16, 17]. Recently, to account for the poor performance of
the MDRD equation in the (near) normal and higher ranges
of GFR, a new equation, the CKD-EPI equation was
developed. It is now considered the preferred estimate of
GFR in renal disease. This formula is similar to the MDRD
but has creatinine-dependent gender differences and gen-
erates higher eGFR at lower creatinine levels. It has a
better performance in subjects with normal or near-normal
renal function, but this equation has not yet been validated
in HF [18]. Given the fact that invasive determination of
GFR is expensive and time consuming, to date, the MDRD
formula is currently considered the golden standard of
estimation of GFR in clinical practice.
Blood urea nitrogen (BUN)
BUN, a waste product of protein catabolism, has been
extensively studied in dialysis patients and is an important
target for removal by (hemo) dialysis, as well as a marker
for the effectiveness of dialysis. Although most clinicians
will use BUN with or without serum creatinine in daily
practice, only in recent years, the relationship of BUN with
outcome in cohorts of patients with HF has been estab-
lished (Table 2). In large cohorts of patients with acute and
chronic HF, an elevated BUN has been shown to be a
strong predictor of morbidity and mortality [19–26]. BUN
was an even better predictor of outcome compared to GFR
in the OPTIME-CHF population [27]. It has been argued
that BUN is much more than a reﬂection of GFR [28]. It is
also largely dependent on protein intake, catabolism, and
tubular reabsorption. The latter is coupled to sodium
reabsorption and may, therefore, reﬂect the extent of for-
ward failure. Together, BUN or urea may be a reﬂection of
both GFR and of the severity of HF, whereas there is also
clear cut impact of nutritional status and catabolic state.
This may be the reason why it possesses strong predictive
abilities, but in terms of estimation of renal function, and
the effect of possible treatment on renal function, BUN
may be a more varying and, therefore, unreliable marker
compared to creatinine and creatinine-based formulas.
Cystatin C
Of all markers that give an estimate of GFR, cystatin C is
the newest, although ﬁrst reports on cystatin C were
already published 30 years ago. Cystatin C is freely ﬁltered
through the glomerulus and completely reabsorbed and
degraded in the tubulus. Its level in the circulation is
therefore an ideal marker of GFR [29]. Cystatin C has been
shown to be superior to serum creatinine as an estimate of
GFR in several different patient populations, in particular,
in the near-normal, normal and higher range, where cre-
atinine-derived measures perform poorly [30]. It is a strong
predictor of outcome in coronary artery disease, diabetes,
but also the general (elderly) population [31–33]. Data on
cystatin C in chronic and acute HF are scarce, but some
studies have shown the prognostic power of cystatin C in
CHF [33, 34]. In acute HF, cystatin C showed independent
prognostic information, even in patients with normal serum
creatinine [35].
However, in HF, no data exist on the reliability of
cystatin C to accurately estimate GFR. In renal disease,
cystatin C has been shown to provide a reliable and less
biased estimate of GFR compared to serum creatinine [36–
38]. Cystatin C is not inﬂuenced by body mass, muscle
turnover, and cachexia, which are important confounders
of serum creatinine [39]. There have been concerns that
cystatin C may be dependent on inﬂammatory status or
smoking, but others have reported no bias by these factors
[32, 40, 41]. Cystatin C levels may be used alone or in a
formula similar to creatinine-based formulas, but in each
circumstance give accurate estimation of GFR, although
Table 2 Relationship between blood urea nitrogen and outcome in heart failure studies
Study Year N Setting BUN (mg/dL) Relative risk for mortality
Lee [25] 2003 4031 ADHF 29 ± 19 1.49 (1.39–1.60) per 10 units increase
Aronson [19] 2004 541 ADHF 34 ± 22 2.3 (1.3–4.1) for quartiles
Heywood [24] 2005 680 CHF 29 ± 20 BUN 30–50: 1.9, BUN[50: 2.2
Shenkman [26] 2007 257 ADHF 33 ± 22 3.6 (1.8–7.3) per log unit increase
Filippatos [21] 2007 302 ADHF 31 ± 17 1.03 (1.00–1.05) per unit increase
Cauthen [20] 2008 444 CHF 14 (6–22) 1.04 (1.03–1.06) per unit increase
Klein [27] 2008 949 CHF 25 (14–41) 1.11 (1.07–1.15) per 5 units increase
Lin [22] 2009 243 CHF 27 ± 17 1.24 (1.02–1.51) for BUN-to-creatinine ratio
Gotsman [23] 2010 362 ADHF 23 (17–29) 1.80 (1.30–2.49), per tertile BUN/creatinine
ADHF Acute decompensated heart failure, BUN Blood urea nitrogen, CHF Chronic heart failure
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123not always superior to creatinine [36, 38]. Whether cystatin
C may give more reliable estimations of changes in GFR
compared to serum creatinine is unknown. From a physi-
ologic perspective, given the totally free ﬁltration through
the glomerulus and total degradation in the tubulus, it is
likely that it may be a more accurate marker of changes in
renal function compared to creatinine [39].
Although cystatin C seems to be superior to creatinine in
estimating GFR and may be at least identical to creatinine in
establishing prognosis, it is far underused in clinical prac-
tice. There are two important reasons and disadvantages of
cystatin C to explain this. First, serum creatinine has been
around for such a long time that clinicians are familiar with
its normal values and in most instances can adequately
estimate GFR for a particular patient with a certain serum
creatinine. For cystatin C, however, there is so little expe-
rience that only few will know what GFR accompanies each
cystatin C level. Secondly, as cystatin C is not routinely
measured, cystatin C measurement is relatively expensive,
especially if it should replace creatinine as a (daily)
assessment of renal function [42]. On the other hand, sev-
eral other markers that have comparable or more expensive
costs to determine have made it into clinical practice in
cardiology, including Troponins and N-terminal brain
natriuretic peptide. It will therefore take a change of mind
from clinicians and researches to eventually replace serum
creatinine with cystatin C in clinical practice, once future
studies will provide more solid information on its routine
use as point estimate and measure of changes in GFR.
Glomerular permeability
The previously mentioned markers give an estimate of
GFR, the ability of the kidney to clear a certain amount of
blood from the waste substances of metabolism. However,
besides a reduction in ﬁltration capabilities or even in the
presence of preserved GFR, glomerular leakage may
develop when glomerular capillary damage occurs. In these
circumstances, larger than normal molecules enter the
ultraﬁltrate of which albumin is the most important one.
When the leakage of albumin exceeds the tubular capacity
of reabsorption, it appears in the urine in abnormal amounts.
Albuminuria
In patients with diabetes, hypertension, and chronic kidney
disease, micro (30–300 mg/gram creatinine) and macro-
albuminuria ([300 mg/gram creatinine) are commonly
observed [43–45]. Importantly, albuminuria has been
advocated as an important therapeutic target in patients with
chronickidneydisease.Evenindependentofbloodpressure,
albuminuria is considered to be an important target for
therapy, although strong evidence to support this is lacking.
Even so, in CKD patients with diabetes, the degree of
reduction in albuminuria was strongly correlated with car-
diovascular outcome and, more importantly, incident HF
[46]. The pathophysiology of albuminuria in general is
considered to be related to endothelial dysfunction,
increasedintraglomerularpressure,andatherosclerosis[47].
Importantly, its pathophysiology, therefore, differs consid-
erably from that of decreased GFR [48]. On the other hand,
there are suggestions that albuminuria in HF may be asso-
ciated with impaired renal perfusion and increased venous
congestion, in analogy to decreased GFR [49–53]. These
two entities deﬁne the clinical syndrome of HF, and there-
fore, it issurprising thatonly recently data onthe prevalence
and prognostic information on albuminuria and proteinuria
in HFhas been published. Van der Wal etal. were the ﬁrst to
show that albuminuria was present in 32% of patients with
HF, compared with 10% of an age and gender-matched
healthy population [54]. In large sub studies of the CHARM
and GISSI-HF trial, micro and macro-albuminuria were not
only prevalent, but also associated with a strongly increased
mortality rate [55, 56]. This was even apparent in patients
without decreased GFR, which may suggest that either
albuminuria may be a very early sign of renal damage/
insufﬁciency as it has been reported in the general popula-
tion,orthatdifferentmechanismsmaycontributetoreduced
GFR and increased albumin excretion. For example, in
general populationstudies,albuminuriawasstronglyrelated
with the presence of diabetes and hypertension and might,
therefore, be a reﬂection of comorbid organ dysfunction in
HF [57]. These substudies assessed albuminuria in morning
spot urine. In a substudy of the Val-HEFT, dipstick-positive
proteinuria (rather than albuminuria) was infrequent, but
still associated with impaired clinical outcome [58]. How-
ever, proteinuria as assessed by dipstick is a less precise,
qualitative, rather than quantitative measurement and is
therefore less sensitive and inaccurate estimate of high
normal, micro or macroalbuminuria.
Importantly, both CHARM and GISSI-HF studies failed
to show a signiﬁcant reduction in albuminuria with either
angiotensin receptor blockade or statin treatment. It is
therefore unlikely that albuminuria may be useful as a
primary target for therapy in patients with HF. However,
albuminuria may serve as marker of prognosis in patients
with HF and as a predictor of HF in patients without car-
diac dysfunction, even when GFR is normal.
Tubulointerstitial damage
Nephrologists increasingly use markers that represent
tubulointerstitial injury to provide a more appropriate
estimation of ‘‘renal function’’. Although most markers
Heart Fail Rev (2012) 17:241–250 245
123have not made it into clinical practice yet, ﬁrst results in
HF patients look promising
N-acetyl-beta-D-glucosaminidase (NAG)
NAG is a lysosomal enzyme that is formed in the proximal
tubule and shed into the urine in response to tubular injury.
It has been extensively studied in experimental and clinical
settings and is a sensitive marker of proximal tubular
damage in renal disease, but also after cardiopulmonary
bypass grafting and diabetic nephropathy [59–61]. NAG is a
prominent predictor of the occurrence of AKI or WRF [60,
62]. In CHF, urinary NAG levels are strongly elevated
compared to age and gender-matched controls [63]. Inter-
estingly, lower renal blood ﬂow was associated with ele-
vated NAG levels, indicating that tubulointerstitial damage
may develop as a result of decreased renal perfusion,
potentially by a decreased cardiac output [63]. Furthermore,
higher NAG levels were associated with poorer clinical
outcome in this group of patients with HF, independent of
GFR. On the other hand, higher levels of NAG are also
found in various other conditions, such as urinary tract
infections, which may limit speciﬁcity [64]. Therefore,
future research is needed in both acute and chronic HF to
further establish the place of NAG as a renal tubular marker.
Kidney injury molecule 1 (KIM-1)
KIM-1 is a transmembrane protein that cannot be found in
urine in normal situations. However, after hypoxic tubular
injury, proximal tubule epithelial cells express KIM-1 at
extremely high levels, which can reach up to 1000-fold
[65]. In experimental and clinical renal disease, KIM-1
urine levels reﬂect the extent of tubulointerstitial levels
[66]. KIM-1 expression in biopsies of renal tissues in
response to tubulointerstitial damage is primarily located at
the proximal tubular epithelial cells and is predominantly
present in areas of early ﬁbrosis [67]. In children under-
going cardiopulmonary bypass grafting, KIM-1 was supe-
rior to NAG in predicting the occurrence of AKI after
surgery [68]. The increase in both markers occurred almost
24 h before a rise in serum creatinine was apparent. KIM-1
(and NAG) may, therefore, possess properties related to the
extent of (chronic) tubulointerstitial damage, but may also
accurately and early predict those patients that are at
increased risk of developing a deterioration in renal
function. Urinary KIM-1 levels decrease in response to
anti-hypertensive treatment with a combination of either
thiazides, a low salt diet or angiotensin receptor blockade,
and the reduction in KIM-1 was correlated with a reduction
in proteinuria [69]. Of note, in animal experiments, the
changes in urinary levels of KIM-1 during renoprotective
intervention reﬂected the changes in tubulointerstitial
KIM-1 expression, suggesting that changes in urinary
KIM-1 levels will have the potential to monitor the course
and response to the intervention of tubulointerstitial dam-
age [70]. As discussed earlier, albuminuria may also exist
in chronic HF. Higher protein loading of the tubule may
have a direct damaging effect on the tubular epithelium
[69]. This can, therefore, be a different pathophysiologic
pathway by which tubular damage and thereby higher
urinary KIM-1 expression may develop. Clinical data on
KIM-1 expression in chronic HF is limited. We recently
found that urinary KIM-1 levels were strongly increased in
patients with stable chronic HF and only mildly impaired
GFR [63]. In fact, even in patients with normal GFR, uri-
nary KIM-1 levels were strongly increased in comparison
with matched control [63]. Importantly, urinary KIM-1
levels at a single point in time predicted outcome in these
patients, independent of GFR. These results further
acknowledge the prevalence a ´nd prognostic importance of
tubulointerstitial damage in chronic HF and the ability of
KIM-1 to identify high risk individuals. To date, no study
evaluated KIM-1 expression in the setting of acute
(decompensated) HF or evaluated the ability of KIM-1 to
predict worsening of renal function in HF. As KIM-1 is
predominantly expressed in response to ischemic tubular
damage, especially the setting of acute HF, KIM-1 may be
of clinical importance in this setting, although studies are
still lacking. Although urinary KIM-1 is highly sensitive to
(proximal) tubulointerstitial damage, it lacks speciﬁcity in
the presence of other (chronic) comorbid organ dysfunc-
tion. For instance, KIM-1 levels are also increased in
patients with hypertension and diabetic nephropathy [67].
As these patients may have a high risk for the development
of HF, the baseline expression of KIM-1 in urine may be
biased in such conditions.
Neutrophil gelatinase-associated lipocalin (NGAL)
NGAL is a small (21kD) protein that is normally detectable
in serum as it is secreted in low amounts in lung, kidney,
trachea, stomach, and colon [71]. Because of its small
molecular weight, it is freely ﬁltered through the glomer-
ulus and completely reabsorbed in the tubules [71]. NGAL
can be measured in plasma or urine. In normal situations,
urine and plasma levels are low. Plasma NGAL levels are
less speciﬁc for (acute) renal disease, as higher levels are
also found in inﬂammation, sepsis, or cancer [71]. Urine
levels are much less affected by these situations, since the
NGAL that appears in the urine is secreted only from the
tubules (plasma NGAL is ﬁltered and totally reabsorbed)
[71, 72]. In AKI, both plasma and urine NGAL rise
strongly, and therefore, the relative contribution of non-
renal origins of NGAL is considered negligible. In
response to tubulointerstitial damage, however, both serum
246 Heart Fail Rev (2012) 17:241–250
123and urinary concentrations may rise op to a 1000-fold and
high concentrations of NGAL are expressed in urine, which
mostly comes from production in the distal nephron (loop
of Henley and collecting ducts) [71–73]. Urinary NGAL
may, therefore, reﬂect occurrence of ischemic tubular
injury in more distal parts of the nephron. However, high
levels of NGAL in urine (and serum) have also been
observed during proximal tubular injury, indicating that the
site-speciﬁc increase in NGAL may be more complex [74].
NGAL measurements may be clinically useful as higher
levels of NGAL are prominent predictors of the occurrence
of AKI or WRF. In a landmark paper, Mishra et al. showed
that higher NGAL serum and urine levels were able to
predict the occurrence of AKI with remarkable speciﬁcity
and sensitivity [73]. Importantly, similar to KIM-1 and
NAG, the rise in NGAL levels preceded the rise in serum
creatinine by over 24 h. Interestingly, administration of
NGAL in experimental setting of acute ischemic renal
injury attenuated tubular injury, suggesting a possible
therapeutic role for NGAL by protecting against tubulo-
interstitial injury by inducing re-epithelialization [75].
Recent reports have studied the relationship between
NGAL and WRF on outcome in acute HF. Higher plasma
NGAL levels were found to predict the occurrence of WRF
in patients admitted with acute HF [76]. A different study
showed that higher plasma NGAL levels were related to a
poorer clinical outcome [77]. In chronic HF, urinary NGAL
levels are strongly increased in comparison with matched
controls [78]. However, NGAL levels did not predict out-
come in this group of CHF patients, in contrast to both
NAG and KIM-1 [63]. Considering the lack of speciﬁcity
of NGAL in the setting of chronic instead of acute renal
failure, the acute rather than the chronic HF patient pop-
ulation may be a more suitable setting for the clinical
implementation of NGAL.
Interleukin 18 (IL-18)
IL-18 is a proinﬂammatory cytokine that is quickly and
highly upregulated in response to AKI in various situations
[79]. It is one of the many proinﬂammatory cytokines, but
IL-18 is particularly interesting given it possible role in
mediation of ischemic renal failure [80]. IL-18 is detect-
able in urine after AKI and a sensitive predictor of AKI in
the setting of cardiopulmonary bypass grafting [80]. In a
comparative analysis, IL-18 levels preceded the rise in
creatinine, but the rise in IL-18 was slower compared to the
rise in NGAL [80]. Importantly, as a proinﬂammatory
cytokine, IL-18 levels are also strongly increased in
inﬂammatory conditions, such as arthritis and sepsis [81].
This limits the speciﬁcity of IL-18 in the setting of mixed
AKI and pronounced inﬂammation. Some studies have
investigated the role of IL-18 as a proinﬂammatory
cytokine in ischemic heart disease. In a small study, plasma
IL-18 levels were increased in patients with HF, and those
who survived had lower baseline plasma IL-18 levels [82].
Interestingly, this study found increased activity of IL-18 in
human myocardium of failing hearts, which may suggest
that IL-18 has pathophysiologic role in the setting of HF.
IL-18 also predicts outcome in ischemic heart disease and,
as such, was a predictor of the incidence of HF [83]. No
studies have investigated the ability of IL-18 to predict
AKI/WRF in the setting of HF.
Fatty acid-binding protein (FABP)
FABPs are proteins that bind selectively to free fatty acids.
There are numerous different FABPs that have tissue-
speciﬁc expression, which include the liver, heart, and
brain [84]. Of these, liver FABP, (L-FABP or FABP-1) and
heart FABP (H-FABP or FABP-3) have been associated
with impaired renal function [85]. Both proteins are
thought to play a role in the energy metabolism of the large
amounts of energy consuming renal tubules. FABP-1
is exclusively found in the proximal tubules, whereas
FABP-3 is localized in the distal tubules [86]. In response
to ischemic injury, FABP-1 and FABP-3 are shed into the
urine and detectable as sensitive and speciﬁc biomarkers of
AKI. FABP-1 may even outperform NGAL and KIM-1 in
AKI [87]. In an animal model, FABP-1 was superior to
NAG in predicting AKI [39]. Further observations suggest
that urinary FABP-1 levels are increased in response to
hypoxia induced by impaired peritubular capillary blood
ﬂow in the kidney, a situation which is likely to exist in a
low perfusion state such as HF [86]. FABP-3 levels may
predict outcome in HF, but the ability to predict AKI has
not yet been studied [88].
Conclusions
The interaction between heart failure and renal impairment
is not static, but comprises of dynamic changes in volume
status, inﬂammatory response, neurohormonal activation
and changes in renal function, by natural course, or in
relation to therapy. These changes may be quick and sub-
stantial, but may also be slow and subtle. Finding the right
marker to predict renal function in all of these situations
may be impossible, but new markers are emerging that
seem to perform better than serum creatinine alone. Some
of these markers may give a good representation of GFR,
such as cystatin C, BUN, while others give information on
glomerular permeability (albuminuria) or tubulointerstitial
damage (NAG, KIM-1, NGAL, and FABP). Importantly,
the latter group (including IL-18) represents markers that
may also predict acute changes in renal function, even
Heart Fail Rev (2012) 17:241–250 247
123before changes in creatinine occur. These markers are
therefore suitable candidates as markers of treatment effect
and as possible targets for therapy. New randomized clin-
ical trials should, therefore, include measurement of these
markers and possibly target these markers to preserve or
even improve renal function in patients with HF.
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